Cortexyme Stock Price and Value Analysis

Should you buy Cortexyme stock? (NASDAQ:CRTX). Let's see how it does in our automated value investing analysis system.

  • This company is solid.
  • This company has amazingly consistent growth!
  • This stock looks overpriced.
  • This company is not making money.
  • This company pays no dividend.

Inside the CRTX Numbers

CRTX Price
(Cortexyme stock price per share)
[?] PE Ratio versus Sector 20% higher than other Healthcare stocks
[?] PE Ratio versus Industry 57% lower than other Biotechnology stocks
[?] Cash Yield -0.08%

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 3,553,428 shares shorted. With 17,841,558 shares available for purchase and an average trading volume over the past 10 trading days of 2,129,330, it would take at least 1.669 days for all of the short holders to cover their shorts.

Is Cortexyme Stock on Sale?

Based on our analysis, we believe that you should not buy Cortexyme right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy CRTX Stock?

Does Cortexyme have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.